Erdoğan İNAL, Meliha LAÇİN, Korhan ASAL, Alper CEYLAN, Ahmet KÖYBAŞIOĞLU, Fikret İLERİ, Sabri USLU

Baş-boyun yassı epitel hücreli SCC karsinomda ferritin, lipid ilişkili sialik asit, karsinoembriyonik antijen, SCC antijeni ve CYFRA 21-1 düzeyleri

Amaç: Baş-boyun yassı epitel hücreli karsinomlarının tanı ve tedavi takibinde bazı tümör belirteçlerinin değeriaraştırıldı.Hastalar ve Yöntemler: Baş-boyun bölgesinde yassı epitel hücreli karsinom saptanan 28 hastada ve benign başboyun tümörlü 20 hastadan oluşan kontrol grubunda ferritin, lipid ilişkili sialik asit LSA , karsinoembriyonik antijen CEA , yassı epitel hücreli karsinom SCC antijeni veCYFRA 21-1 düzeyleri tedavi öncesi ve tedavi sonrası birinci ve üçüncü aylarda olmak üzere ölçüldü.Bulgular: Bu belirteçlerin duyarlılığı ferritin için %10.7, LSAiçin %89.3, CEA için %21.4, SCC antijeni için %42.9,CYFRA 21-1 için %14.3 bulundu. Tüm belirteçler için özgüllük %100 bulundu. Birlikte kullanıldığında, CEA ve LSA’nınduyarlılığı %96.4’e yükseldi. Tedavi sonrasında ferritin,CEA, SCC antijeni ve LSA düzeylerinde anlamlı düşüş görüldü. Araştırılan belirteçlerin düzeyleri ile lenf nodu metastazı, evre ve tümörün histolojik diferansiyasyonu arasındaanlamlı ilişki saptanmadı. Sadece ferritin ve LSA düzeylerinin tümör boyutu ile ilişkili olduğu bulundu. Yassı hücreli karsinom antijeninin lokorejyonel nüks ve mortalite görülen olgularda yüksek seviyesini koruduğu izlendi.Sonuç: İncelenen üç belirtecin LSA, CEA ve SCC antijeni baş-boyundaki yassı epitel hücreli karsinomları değerlendirmede önemli olduğu ve bunların birlikte kullanımı ile duyarlılık ve özgüllük değerlerinin yükselebileceği sonucuna varıldı

Anahtar Kelimeler:

Karsinom, yassı epitel hücreli/kan, baş-boyunneoplazileri/kan, tümör belirteci, biyolojik/kan

The significance of ferritin, lipid-associated sialic acid, CEA, squamous celi carcinoma SCC antigen, and CYFRA 21-1 levels in SCC of the head and neck

Objectives: We investigated the value of some tumor markers in the diagnosis and treatment follow-up of squa- mous celi carcinoma of the head and neck.Patients and Methods: Ferritin, lipid-associated sialic acid LSA , carcinoembryonic antigen CEA , squamous celi car cinoma SCC antigen and CYFRA 21-1 levels were determined in 28 patients with squamous celi carcinoma and in a control group of 20 patients with benign lesions of the head and neck. The measurements were made before treatment and in the first and third months of treatment.Results: The sensitivity rates were as follovvs: 10.7% for ferritin, 89.3% for LSA, 21.4% for CEA, 42.9% for SCC antigen, and 14.3% for CYFRA 21-1. The specificity was 100% for ali the markers. The sensitivity increased to 96.4% when CEA and LSA were used in combination. Declines in the levels after treatment were significant for ferritin, CEA, SCC antigen, and LSA. No significant relationship was found betvveen the marker levels and lymph node metastasis, stage, and histologic differentiation of the tumors. Only ferritin and LSA levels were correlated with tumor size. Squamous celi carcinoma antigen was the only marker that manifested high levels in patients who developed locoregional recurrence and/or mortality.Conclusion: Of the markers studied, LSA, CEA and SCC antigen may be of value in the evaluation of squamous celi carcinoma of the head and neck. Sensitivity and specificity rates may increase when they are used in combination.

Keywords:

Carcinoma, squamous cell/blood, head and neck neoplasms/blood, tumor markers, biological/blood,

PDF

___

Schantz SP. Biologic markers, cellular differentiation, and metastatic head and neck cancer. Eur Arch Otorhinolaryngol 1993;250:424-8.
Vinzenz K, Schonthal E, Zekert F, Wunderer S. Diagnosis of head and neck carcinomas by means of immunological tumour markers (Beta-2-microglobu- lin, immunoglobulin E, ferritin, N-acetyl-neuraminic acid, phosphohexose-isomerase). J Craniomaxillofac Surg 1987;15:270-7.
Kiricuta I, Bojan O, Comes R, Cristian R. Significance of serum fucose, sialic acid, haptoglobine and phos- pholipids levels in the evolution and treatment of breast cancer. Arch Geschwulstforsch 1979;4:106-12.
Silver HK, Rangel DM, Morton DL. Serum sialic acid elevations in malignant melanoma patients. Cancer 1978;41:1497-9.
Maxim PE, Veltri RW. Serum ferritin as a tumor mark- er in patients with squamous cell carcinoma of the head and neck. Cancer 1986;57:305-11.
Papenhausen PR, Emeson EE, Croft CB, Borowiecki B. Ferritin-bearing lymphocytes in patients with cancer. Cancer 1984;53:267-71.
Gold P, Freedman SO. Demonstration of tumor-specif- ic antigens in human colonic carcinomata by immuno- logical tolerance and absorption techniques. J Exp Med 1965;121:439-62.
Kato H, Torigoe T. Radioimmunoassay for tumor anti- gen of human cervical squamous cell carcinoma. Cancer 1977;40:1621-8.
Coggi G, Dell’Orto P, Braidotti P, Coggi A, Viale G. Coexpression of intermediate filaments in normal and neoplastic human tissues: a reappraisal. Ultrastruct Pathol 1989;13:501-14.
Oremek GM, Siekmeier R, Zirker M, Kirsten R. The significance of Cyfra 21-1 in pneumological differen- tial diagnosis. Lab Med 1994;18:100-4.
Katopodis N, Stock CC. Improved method to deter- mine lipid bound sialic acid in plasma or serum. Res Commun Chem Pathol Pharmacol 1980;30:171-80.
Veltri RW, Maxim PE. Tumor immunity and tumor markers in head and neck cancer. In: Wolf GT, editor. Cancer treatment and research, head and neck oncolo- gy. 1st ed. Boston: Martin Nijhoff Publishers; 1984. p. 411-30.
Bhatavdekar JM, Vora HH, Goyal A, Shah NG, Karelia NH, Trivedi SN. Significance of ferritin as a marker in head and neck malignancies. Tumori 1987;73:59-63.
Dreyfuss AI, Clark JR, Andersen JW. Lipid-associated sialic acid, squamous cell carcinoma antigen, carci- noembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer 1992;70:2499-503.
Fischer F, Egg G. N-acetylneuraminic acid (sialic acid) as a tumor marker in head and neck cancers. HNO 1990;38:361-3. [Abstract]
Klapan I, Katic V, Culo F, Sabolovic D, Cuk V, Fumic K, et al. Lipid-bound sialic acid, prostaglandin E and his- tamine in head and neck cancer. Eur J Cancer 1993; 29A:839-45.
Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C. Tumor size-dependent elevations of serum ganglio- sides in patients with head and neck carcinomas. Biochem Int 1989;18:759-65.
Fischbach W, Meyer T, Barthel K. Squamous cell carci- noma antigen in the diagnosis and treatment follow- up of oral and facial squamous cell carcinoma. Cancer 1990;65:1321-4.
Eibling DE, Johnson JT, Wagner RL, Su S. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope 1989;99:117-24.
Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 1996;16:3117-24.
Silverman NA, Alexander JC Jr, Chretien PB. CEA lev- els in head and neck cancer. Cancer 1976;37:2204-11.
Hoffmann J, Munz A, Krimmel M, Alfter G. Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma. J Oral Maxillofac Surg 1998;56:1390-3.
Ogawa T, Tsurusako Y, Kimura N, Nishioka S, Akagi H, Nishizaki K, et al. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol Suppl 1999;540:72-6.
Schroder M, Meyer T. CEA studies in squamous cell carcinomas of the head and neck. HNO 1986;34:334- 42. [Abstract]
Niemann AM, Goeroegh T, Gottschlich S, Lippert BM, Werner JA. Cut-off value determination of CYFRA 21- 1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 1997;17:2859-60.
Ropka ME, Goodwin WJ, Levine PA, Sasaki CT, Kirchner JC, Cantrell RW. Effective head and neck tumor markers. The continuing quest. Arch Otolaryngol Head Neck Surg 1991;117:1011-4.
Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, et al. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1995;121:177-81.
Rassekh CH, Johnson JT, Eibling DE. Circulating mark- ers in squamous cell carcinoma of the head and neck: a review. Eur J Cancer B Oral Oncol 1994;30B:23-8.